linc-ADAIN, a human adipose lincRNA, regulates adipogenesis by modulating KLF5 and IL-8 mRNA stability
Cell Reports · 2024
DOI: 10.1016/j.celrep.2024.114240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2024. Verfasst von Marcella E O'Reilly und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY, USA. Hauptthemen laut MEDLINE: Adipogenesis, Interleukin-8, Kruppel-Like Transcription Factors, RNA Stability. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Adipose tissue remodeling and dysfunction, characterized by elevated inflammation and insulin resistance, play a central role in obesity-related development of type 2 diabetes (T2D) and cardiovascular diseases. Long intergenic non-coding RNAs (lincRNAs) are important regulators of cellular functions. Here, we describe the functions of linc-ADAIN (adipose anti-inflammatory), an adipose lincRNA that is downregulated in white adipose tissue of obese humans. We demonstrate that linc-ADAIN knockdown (KD) increases KLF5 and interleukin-8 (IL-8) mRNA stability and translation by interacting with IGF2BP2. Upregulation of KLF5 and IL-8, via linc-ADAIN KD, leads to an enhanced adipogenic program and adipose tissue inflammation, mirroring the obese state, in vitro and in vivo. KD of linc-ADAIN in human adipose stromal cell (ASC) hTERT adipocytes implanted into mice increases adipocyte size and macrophage infiltration compared to implanted control adipocytes, mimicking hallmark features of obesity-induced adipose tissue remodeling. linc-ADAIN is an anti-inflammatory lincRNA that limits adipose tissue expansion and lipid storage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY, USA.
- Proteomics and Macromolecular Crystallography Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
- Department of Statistics, Mailman School of Public Health, Columbia University Medical Center, New York, NY, USA.
- Division of Molecular Genetics, Department of Pediatrics, Columbia University Medical Center, New York, NY, USA.
- Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
- Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NCATS NIH HHS
- American Heart Association
- National Institutes of Health
- National Institute of Health
Zitieren
APA
O'Reilly, M. E., Ho, S., Coronel, J., Zhu, L., Liu, W., Xue, C., Kim, E., Cynn, E., Matias, C. V., Soni, R. K., Wang, C., Ionita-Laza, I., Bauer, R. C., Ross, L., Zhang, Y., Corvera, S., Fried, S. K., & Reilly, M. P. (2024). linc-ADAIN, a human adipose lincRNA, regulates adipogenesis by modulating KLF5 and IL-8 mRNA stability. Cell Reports. https://doi.org/10.1016/j.celrep.2024.114240
Vancouver
O'Reilly ME, Ho S, Coronel J, Zhu L, Liu W, Xue C, et al. linc-ADAIN, a human adipose lincRNA, regulates adipogenesis by modulating KLF5 and IL-8 mRNA stability. Cell Reports. 2024. doi:10.1016/j.celrep.2024.114240
BibTeX
@article{OReilly2024,
author = {O'Reilly, Marcella E and Ho, Sebastian and Coronel, Johana and Zhu, Lucie and Liu, Wen and Xue, Chenyi and Kim, Eunyoung and Cynn, Esther and Matias, Caio V and Soni, Rajesh Kumar and Wang, Chen and Ionita-Laza, Iuliana and Bauer, Robert C and Ross, Leila and Zhang, Yiying and Corvera, Silvia and Fried, Susan K and Reilly, Muredach P},
title = {linc-ADAIN, a human adipose lincRNA, regulates adipogenesis by modulating KLF5 and IL-8 mRNA stability},
journal = {Cell Reports},
year = {2024},
doi = {10.1016/j.celrep.2024.114240}
}
EUVIMED